KURA ONCOLOGY, INC.

(KURA)
  Report
Real-time Estimate Cboe BZX  -  05/19 12:34:00 pm EDT
12.10 USD   +1.64%
05/04KURA ONCOLOGY : Q1 Earnings Snapshot
AQ
05/04KURA ONCOLOGY, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
05/04TRANSCRIPT : Kura Oncology, Inc., Q1 2022 Earnings Call, May 04, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
All news about KURA ONCOLOGY, INC.
05/04KURA ONCOLOGY : Q1 Earnings Snapshot
AQ
05/04KURA ONCOLOGY, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RE..
AQ
05/04TRANSCRIPT : Kura Oncology, Inc., Q1 2022 Earnings Call, May 04, 2022
CI
05/04Kura Oncology Reports First Quarter 2022 Financial Results
AQ
05/04Kura Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
04/27Kura Oncology to Report First Quarter 2022 Financial Results
AQ
04/08Kura Oncology Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergenc..
AQ
04/08Kura Oncology, Inc. Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Em..
CI
03/15TRANSCRIPT : Kura Oncology, Inc. Presents at Barclays Global Healthcare Conference 2022, M..
CI
03/08Kura Oncology Announces Multiple Abstracts Accepted for Presentation at AACR Annual Mee..
AQ
02/28Kura Oncology to Participate in Two Upcoming Investor Conferences
AQ
02/25SVB Leerink Lowers Kura Oncology's Price Target to $28 From $41, Maintains Outperform R..
MT
02/25Credit Suisse Lifts Kura Oncology's Price Target to $27 from $25, Notes Rich Catalyst L..
MT
02/24KURA ONCOLOGY, INC. : Entry into a Material Definitive Agreement, Termination of a Materia..
AQ
02/24KURA ONCOLOGY : Reports Fourth Quarter and Full Year 2021 Financial Results - Form 8-K
PU
02/24KURA ONCOLOGY : Q4 Earnings Snapshot
AQ
02/24TRANSCRIPT : Kura Oncology, Inc., Q4 2021 Earnings Call, Feb 24, 2022
CI
02/24KURA ONCOLOGY, INC. Management's Discussion and Analysis of Financial Condition and Re..
AQ
02/24Kura Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
02/24Kura Oncology Reports Fourth Quarter and Full Year 2021 Financial Results
AQ
02/24Kura Oncology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, ..
CI
02/17Kura Oncology to Report Fourth Quarter and Full Year 2021 Financial Results
AQ
02/15Jefferies Financial Initiates Kura Oncology at Buy, Sets Price Target at $35
MT
02/14Credit Suisse Lifts Kura Oncology's Price Target to $25 from $21, Maintains Outperform ..
MT
02/10Kura Oncology to Participate in SVB Leerink Global Healthcare Conference
GL
02/07Alector Appoints Marc Grasso as CFO
MT
02/02Kura Oncology Finance Chief Marc Grasso to Step Down
MT
02/01KURA ONCOLOGY, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
02/01Kura Oncology Expands Leadership Team with Key Promotions
GL
02/01Kura Oncology, Inc. Announces Executive Changes
CI
02/01Kura Oncology, Inc. Announces Executive Changes
CI
01/21Kura Oncology Receives FDA Authorization to Proceed with Phase 1b Study of KO-539 in Ac..
AQ
01/20FDA Lifts Hold Kura Oncology's KOMET-001 Phase 1b Study of KO-539 Patients With Relapse..
MT
01/20KURA ONCOLOGY, INC. : Other Events (form 8-K)
AQ
01/20Kura Oncology Receives FDA Authorization to Proceed with Phase 1b Study of KO-539 ináAc..
AQ
01/20Kura Oncology, Inc. Receives FDA Authorization to Proceed with Phase 1b Study of KO-539..
CI
2021Kura Oncology Initiates Dosing in Phase 1/2 Clinical Trial of Head, Neck Cancer Combo T..
MT
2021Kura Oncology Doses First Patient in Phase 1/2 Clinical Trial of Tipifarnib in Combinat..
GL
2021Kura Oncology, Inc. Doses First Patient in Phase 1/2 Clinical Trial of Tipifarnib in Co..
CI
2021SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kura ..
PR
2021Kura Oncology Reports 56% Overall Response Rate in T-Cell Lymphoma Drug Study
MT
2021Kura Oncology Reports Final Results from Phase 2 Study of Tipifarnib in T-Cell Lymphoma
AQ
2021Kura Oncology, Inc. Reports Final Results from Phase 2 Study of Tipifarnib in T-Cell Ly..
CI
2021Kura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Menin Inhib..
GL
2021Credit Suisse Adjusts Kura Oncology's Price Target to $21 From $40, Keeps Outperform Ra..
MT
2021Health Care Stocks Unable to Return to Positive Ground By Wednesday Close
MT
2021Kura Oncology Shares Sink After FDA Imposes Partial Hold on Phase 1b Study of KO-539
MT
2021Health Care Stocks Marginally Lower After Paring Losses
MT
2021HC Wainwright Adjusts Price Target on Kura Oncology to $32 From $43, Maintains Buy Rati..
MT
2021Wedbush Cuts Kura Oncology's Price Target to $40 From $53 After KO-539 Partial Clinical..
MT
2021Wall Street Set to Open in Red Territory; US GDP Growth Upwardly Revised in Q3
MT
2021Health Care Stocks Mixed Premarket Wednesday
MT
2021Health Care
MT
2021TRANSCRIPT : Kura Oncology, Inc. - Special Call
CI
2021Top Premarket Decliners
MT
2021Kura Oncology Says US FDA Places Study of KO-539 on Partial Hold Following Patient Deat..
MT
2021KURA ONCOLOGY, INC. : Other Events (form 8-K)
AQ
2021Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid Leukemia
AQ
2021Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid Leukemia
CI
2021Kura Oncology to Participate in Two Upcoming Investor Conferences
GL
2021TRANSCRIPT : Kura Oncology, Inc. Presents at 30th Annual Credit Suisse Healthcare Conferen..
CI
2021KURA ONCOLOGY : Q3 Earnings Snapshot
AQ
2021Kura Oncology Reports Third Quarter 2021 Financial Results - Form 8-K
PU
2021Kura Oncology - Corporate Presentation - November 2021
PU
2021TRANSCRIPT : Kura Oncology, Inc., Q3 2021 Earnings Call, Nov 04, 2021
CI
2021KURA ONCOLOGY, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RE..
AQ
2021Kura Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ende..
CI
2021Kura Oncology Reports Third Quarter 2021 Financial Results
AQ
2021Kura Oncology to Participate in Credit Suisse Healthcare Conference
GL
2021Kura Oncology to Report Third Quarter 2021 Financial Results
GL
2021KURA ONCOLOGY : Appoints Teresa Bair as Chief Legal Officer
AQ
2021KURA ONCOLOGY : Appoints Teresa Bair asáChief Legal Officer
GL
2021Kura Oncology, Inc. Appoints Teresa Bair as Chief Legal Officer
CI
2021KURA ONCOLOGY : Corporate Presentation - September 2021
PU
2021KURA ONCOLOGY : to Participate in Two Upcoming Investor Conferences
AQ
1  2  3  4  5  6  7Next
Upcoming event on KURA ONCOLOGY, INC.